Piper Sandler Maintains Overweight on Xeris Biopharma Holdings, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Xeris Biopharma Holdings (NASDAQ:XERS) but reduced the price target from $5 to $4.

November 10, 2023 | 10:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Xeris Biopharma Holdings but lowered the price target from $5 to $4, indicating a positive outlook but with reduced expectations.
While the Overweight rating suggests that Piper Sandler is optimistic about Xeris Biopharma's future performance, the reduction in the price target could reflect a reassessment of potential growth or risks, possibly leading to a neutral short-term impact on the stock price as investors digest the mixed signals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100